Cns Spectrums

• 

  Publication Venue For

  • Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus..  23:402-413. 2018
  • Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials..  19:324-329. 2014
  • Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.  1-10. 2013
  • Attitudes toward borderline personality disorder: a survey of 706 mental health clinicians..  16:67-74. 2011
  • White matter hyperintensities and their association with suicidality in major affective disorders: a meta-analysis of magnetic resonance imaging studies..  15:375-381. 2010
  • Evaluation of the Effects of Severe Depression on Global Cognitive Function and Memory..  15:304-313. 2010
  • Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment..  15:285-287. 2010
  • Understanding therapeutic equivalence in epilepsy..  15:112-123. 2010
  • The clinical future of repetitive transcranial magnetic stimulation and depression: Separating hope from hype.  15:554-557. 2010
  • FDA considers classification of ECT..  14:668-670. 2009
  • THE TREATMENT OF PRIMARY INSOMNIA.  14:6-10. 2009
  • The role of non-pharmacologic approaches in the management of fibromyalgia..  14:10-12. 2009
  • The treatment of primary insomnia..  14:6-10. 2009
  • Decision-making and prepotent response inhibition functions in excessive internet users..  14:75-81. 2009
  • Neuropsychological characterization of dementia patients..  13:10-13. 2008
  • Comorbid HIV encephalopathy and cocaine use as a risk factor for new-onset seizure disorders..  13:230-234. 2008
  • Impulse-control disorders in Parkinson's disease.  13:690-698. 2008
  • Neuropsychological characterization of dementia patients.  13:10-13. 2008
  • Long-term issues in the treatment of sleep disorders..  12:1-14. 2007
  • Coenzyme Q10: a review of its promise as a neuroprotectant..  12:62-68. 2007
  • The Morbidity of Insomnia.  12:6-8. 2007
  • Resilience: Determinants, measurement, and treatment responsiveness.  11:5-12. 2006
  • The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials..  11:788-799. 2006
  • Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial..  11:625-639. 2006
  • Introduction: An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.  11:4-8. 2006
  • Transdermal selegiline: the new generation of monoamine oxidase inhibitors..  11:363-375. 2006
  • Refractory calculation-induced idiopathic generalized epilepsy: A case report and review of the literature.  11:50-51. 2006
  • Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD..  10:35-43. 2005
  • Statins and cognition: what can we learn from existing randomized trials?.  10:867-874. 2005
  • Safety Considerations in Pharmacotherapy of Bipolar Disorder.  9:16-26. 2004
  • Safety considerations in pharmacotherapy of bipolar disorder.  9:16-26. 2004
  • Safety considerations in pharmacotherapy of bipolar disorder..  9:16-26. 2004
  • Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies..  9:763-772. 2004
  • New Challenges for Anxiety Disorders: Where Treatment, Resilience, and Economic Priority Converge.  9:1-9. 2004
  • Managing the risks of repetitive transcranial stimulation..  8:489. 2003
  • New developments in electroconvulsive therapy and magnetic seizure therapy..  8:529-536. 2003
  • How well does cognitive-behavioral therapy treat symptoms of complex PTSD? An examination of child sexual abuse survivors within a clinical trial..  8:340-355. 2003
  • Response of the norepinephrine system to antidepressant drugs.  6:679-684. 2001
  • Adverse-effect profile of kava..  6:848-853. 2001
  • Evaluating medicinal herbs..  6:826. 2001
  • The self-assessment of resilience and anxiety: psychometric properties..  6:854-857. 2001
  • The use of valerian in neuropsychiatry..  6:841-847. 2001
  • Protein kinase a in major depression: the link between hypothalamic-pituitary-adrenal axis hyperactivity and neurogenesis..  6:565-572. 2001
  • Combination pharmacotherapy in alcoholism: a novel treatment approach..  5:70-76. 2000
  • Apathy in neuropsychiatric disorders.  4:31-50. 1999
  • A Consensus Meeting on Effective Research Practice in PTSD.  3:6-10. 1998
  • Recognizing and treating nonmotor disorders associated with Parkinson's disease.  3:41-45. 1998
  • The Role of Serotonin in Posttraumatic Stress Disorder: Neurobiology and Pharmacotherapy.  3:42-51. 1998
  • Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.  2:41-55. 1997
  • Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.  2:41-55. 1997
  • Refractory calculation-induced idiopathic generalized epilepsy. A case report and review of the literature 2006